November 18, 2016
Concordia International Corp. Script Tracker - Week Ended Nov 11th
Our view: Given recent U.S. product and pricing volatility, we believe it is important to provide investors with a weekly in-depth view of script trends.
Key points:
Plaquenil AG TRx up 1.0% WoW, outperforms broader market. Plaquenil AG (Prasco) TRx were up 1.0% WoW vs. up 0.2% the prior week. Total hydroxychloroquine (broader plaquenil market) TRxs were down 1.4% WoW and Prasco's market share (Concordia AG) currently sits at 38.9% of TRx vs. 38.0% the prior week. We have outlined Plaquenil/ hydroxychloroquine market share trends in Exhibit 2. As previously noted, we believe Plaquenil AG pricing decreased by ~40% in early Q3 and we note that Concordia confirmed that Plaquenil AG is seeing further pricing pressure due to the Actavis generic (1.6% market share).
Lanoxin AG TRx down 5.4% WoW. Par's (AG) market share was up slightly to 34.1% from 33.6%, Sun Pharma's market share decreased from 7.4% to 6.7% this week, WestWard Pharma's share decreased from 8.6% to 8.3%, Lannett saw its share decrease from 24.8% to 24.5%, and Impax's share increased slightly to 25.4% from 25.1%. The Lanoxin AG (Par Pharma) saw TRx decrease 5.4% WoW vs. a 6.1% increase last week. The broader market saw TRx flat WoW. We have outlined Lanoxin/Digoxin market trends in Exhibit 3.
Donnatal TRx down 6.8% WoW. As previously noted, we have been monitoring the market share of several IBS drugs that target both IBS- C and IBS-D, due to the launch of Allergan's Viberzi in December (TRx up 3.3% WoW). Donnatal NRx were down 2.0% WoW vs. down 8.4% the prior week and TRx were down 6.8% WoW vs. down 4.3% the prior week. Donnatal's current market share (TRx) is 1.5%; Xifaxan holds a 15.9% market share, Viberzi has a 4.3% share, Amitiza has a 26.6% share, and Linzess has a 51.4% share. Exhibit 5 shows Donnatal weekly NRx and TRx trends.
Other CXRX products: Nilandron TRx down 12% WoW, Dibenzyline AG TRx up 30% WoW, and Kapvay TRx up 10% WoW. Nilandron saw TRx of 29 down 12.1% WoW. We note that ANI Pharmaceuticals had a generic version of Nilandron approved by the FDA on July 18th. The ANI generic saw TRx decrease 51.7% WoW to 28 TRxs. We anticipate that CXRX will launch an AG before year-end